COSMOS HEALTH INC. - C

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

15 May 2025 11:30:35 By Nasdaq GlobeNewswire

Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

15 May 2025 06:30:39 By Nasdaq GlobeNewswire

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

07 May 2025 11:30:10 By Nasdaq GlobeNewswire

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

06 May 2025 10:40:33 By Nasdaq GlobeNewswire

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

30 Apr 2025 09:50:09 By Nasdaq GlobeNewswire

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

16 Apr 2025 09:45:15 By Nasdaq GlobeNewswire

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

09 Apr 2025 10:40:47 By Nasdaq GlobeNewswire

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

08 Apr 2025 07:45:34 By Nasdaq GlobeNewswire